BioPharma Credit PLC (LON: BPCR)
London
· Delayed Price · Currency is GBP · Price in USD0.884
0.00 (0.00%)
Nov 22, 2024, 4:42 PM BST
BioPharma Credit Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Cash & Equivalents | 37.14 | 135.05 | 120.53 | 94.71 | 193.27 | 296.64 | Upgrade
|
| Cash & Short-Term Investments | 37.14 | 135.05 | 120.53 | 94.71 | 193.27 | 296.64 | Upgrade
|
| Cash Growth | -45.28% | 12.05% | 27.26% | -51.00% | -34.85% | -18.41% | Upgrade
|
| Accounts Receivable | 36.88 | 20.23 | 19.73 | 9.59 | 0 | 15.87 | Upgrade
|
| Other Receivables | 0.13 | 0.09 | 0.11 | 0.42 | 0.21 | 0.34 | Upgrade
|
| Receivables | 37.01 | 20.32 | 19.84 | 10.01 | 0.21 | 16.21 | Upgrade
|
| Total Current Assets | 74.15 | 155.37 | 140.37 | 104.72 | 193.48 | 312.84 | Upgrade
|
| Long-Term Investments | 1,157 | 1,201 | 1,224 | 1,266 | 1,195 | 1,116 | Upgrade
|
| Total Assets | 1,232 | 1,357 | 1,364 | 1,371 | 1,388 | 1,429 | Upgrade
|
| Accrued Expenses | 3.45 | 15.87 | 24.35 | 6.34 | 9.39 | 24.5 | Upgrade
|
| Other Current Liabilities | - | - | 1.95 | - | - | - | Upgrade
|
| Total Current Liabilities | 3.45 | 15.87 | 26.3 | 6.34 | 9.39 | 24.5 | Upgrade
|
| Long-Term Unearned Revenue | 0.09 | - | 0.26 | 0.56 | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | - | 0.73 | Upgrade
|
| Total Liabilities | 3.54 | 15.87 | 26.56 | 6.9 | 9.39 | 25.24 | Upgrade
|
| Common Stock | 13.74 | 13.74 | 13.74 | 13.74 | 13.74 | 13.74 | Upgrade
|
| Additional Paid-In Capital | 607.13 | 607.13 | 607.13 | 607.13 | 607.13 | 607.13 | Upgrade
|
| Retained Earnings | 607.21 | 720 | 716.59 | 742.85 | 758.05 | 782.87 | Upgrade
|
| Shareholders' Equity | 1,228 | 1,341 | 1,337 | 1,364 | 1,379 | 1,404 | Upgrade
|
| Total Liabilities & Equity | 1,232 | 1,357 | 1,364 | 1,371 | 1,388 | 1,429 | Upgrade
|
| Net Cash (Debt) | 37.14 | 135.05 | 120.53 | 94.71 | 193.27 | 296.64 | Upgrade
|
| Net Cash Growth | -45.28% | 12.05% | 27.26% | -51.00% | -34.85% | -18.41% | Upgrade
|
| Net Cash Per Share | 0.03 | 0.10 | 0.09 | 0.07 | 0.14 | 0.22 | Upgrade
|
| Filing Date Shares Outstanding | 1,199 | 1,254 | 1,319 | 1,374 | 1,374 | 1,374 | Upgrade
|
| Total Common Shares Outstanding | 1,219 | 1,303 | 1,319 | 1,374 | 1,374 | 1,374 | Upgrade
|
| Working Capital | 70.7 | 139.5 | 114.06 | 98.38 | 184.08 | 288.34 | Upgrade
|
| Book Value Per Share | 1.01 | 1.03 | 1.01 | 0.99 | 1.00 | 1.02 | Upgrade
|
| Tangible Book Value | 1,228 | 1,341 | 1,337 | 1,364 | 1,379 | 1,404 | Upgrade
|
| Tangible Book Value Per Share | 1.01 | 1.03 | 1.01 | 0.99 | 1.00 | 1.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.